摘要
目的:系统评价尼莫地平联合氟桂利嗪治疗偏头痛的有效性和安全性。方法:通过检索Pub Med、中国知网、维普以及万方数据库,根据纳入标准筛选公开发表的尼莫地平联合氟桂利嗪防治偏头痛的随机对照试验的文献,利用Jadad量表进行质量评价,并使用Review Manager 5.3软件对纳入研究进行Meta分析。结果:经过文献的质量评价后,一共纳入10篇文献,试验组423例,治疗有效例数为398例,对照组423例,治疗有效例数为324例。Meta分析表明尼莫地平联合氟桂利嗪组与单用氟桂利嗪组比较差异有统计学意义[OR=4.87,95%CI(3.07,7.74),P<0.01],联合用药的效果比单用氟桂利嗪更好。根据剂量和疗程进行亚组分析,结果显示亚组间无异质性(I^2=0),不同亚组均有治疗效果。联合用药的不良反应与单用氟桂利嗪相比差异有统计学意义[OR=0.41,95%CI(0.20,0.85),P=0.02]。试验组在治疗后头痛发作次数、持续时间、伴随症状、视觉模糊评分(VAS)等与对照组相比差异有统计学意义(P<0.01)。结论:本研究表明尼莫地平联合氟桂利嗪防治偏头痛的效果优于单独使用氟桂利嗪,且安全性良好。
AIM： To evaluate the therapy efficacy and safety of nimodipine combined with flunarizine for preventing and treating migraine. METHODS： Eligible papers about randomized controlled trials of nimodipine combined with flunarizine for preventing and treating migraine and published between 2000 and 2017 were retrieved from Pub Med and from online Chinese periodicals,the full-text databases of Wan Fang,VIP and the Chinese National Knowledge Infrastructure. Jadad scale was used to assess the quality of included articles and a meta-analysis was performed by Rev Man 5. 3 software.RESULTS： A total of ten papers were included finally after assessing the quality of studies. A total of423 people were in the experimental group,in which398 cases were effective. The control group was423,in which 324 cases were effective. Meta-analysis showed that there was a significant difference between experimental group and control group[OR =4. 87,95% CI（ 3. 07,7. 74）,P〈0. 01]. Subgroup analysis was performed based on dose and course of treatment. The result showed that it had no heterogeneity between subgroups and different subgroups all had treatment effect. The difference of adverse effect was statistical between two groups[OR = 0. 41,95%CI（ 0. 20,0. 85）,P = 0. 02]. After treatment,symptoms score evaluation of experimental group was better than the control group（ P〈0. 01）. CONCLUSION： The nimodipine combined with flunarizine showed better efficacy and safety for migraine compared with flunarizine alone.
作者
邵姚君
郑童
王艳秋
刘凌
姚应水
SHAO Yaojun;ZHENG Tong;WANG Yanqiu;LIU Ling;YAO Yingshui(Department of Preventive Medicine,Wannan Medical College,Wuhu 241002,Anhui,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2018年第6期646-652,共7页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
安徽省教育厅省级质量工程-名师工作室(2014msgzs151)
